Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

Francesco Pantano, Marco Russano, Alfredo Berruti, Giovanni Mansueto, Maria R. Migliorino, Vincenzo Adamo, Giuseppe Aprile, Alain Gelibter, Corrado Ficorella, Alfredo Falcone, Antonio Russo, Michele Aieta, Michele Maio, Olga Martelli, Sandro Barni, Andrea Napolitano, Elisa Roca, Silvia Quadrini, Daniela Iacono, Alessandro RussoLorenzo Calvetti, Mario A. Occhipinti, Alessio Cortellini, Enrico Vasile, Francesco Passiglia, Marco Imperatori, Luana Calabrò, Anna M. Di Giacomo, Fausto Petrelli, Giulia Pasquini, Tindara Franchina, Olga Venditti, Salvatore Intagliata, Antonio Galvano, Iacopo Fioroni, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Immune-checkpoint inhibitors have radically changed the treatment landscape of Non-Small-Cell Lung Cancer (NSCLC). It is still unclear whether specific clinical characteristics might identify those patients benefiting from immunotherapy more than others. The aim of this study was to identify clinical characteristics associated with disease-specific survival (DSS), time-to-treatment failure (TTF), objective responses (OR) and progressive disease (PD) in NSCLC patients treated with Nivolumab. Methods: This was a multicenter retrospective study conducted on 294 patients treated with Nivolumab for advanced NSCLC. Results: Of the more than 50 variables analyzed, five showed a significant correlation with DSS: ECOG PS, size of the biggest brain metastasis, number of metastatic sites, toxicity, and malignant pleural effusion. Three variables significantly correlated with TTF: malignant pleural effusion, number of metastatic sites, number of liver metastases. Malignant pleural effusion was the only variable showing a significant correlation with OR, as well as the only one correlating with all the endpoints of the study. Conclusions: This study identified clinical characteristics associated with survival and response during treatment with Nivolumab in NSCLC patients. The unfavorable association between malignant pleural effusion and objective response is a novel finding with important translational implications.

Original languageEnglish
Pages (from-to)319-326
Number of pages8
JournalExpert Opinion on Biological Therapy
Volume20
Issue number3
DOIs
Publication statusPublished - Mar 3 2020

Keywords

  • Immunotherapy
  • malignant pleural effusion
  • Nivolumab
  • non-Small-Cell Lung Cancer

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Fingerprint

Dive into the research topics of 'Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab'. Together they form a unique fingerprint.

Cite this